Placebo News and Research

RSS

Enrollment completed in Impax Pharmaceuticals' APEX-PD trial of IPX066

Impax Pharmaceuticals, the brand products division of Impax Laboratories, Inc., today announced that it has completed enrollment of its APEX-PD trial. APEX-PD is a multinational Phase III trial of its late-stage drug candidate IPX066 in subjects with early Parkinson's disease.

16 Apr 2010

Vertex Pharmaceuticals announces results from Phase 1b clinical trial of VX-222

In conjunction with an oral presentation at the 45th Annual Meeting of the European Association for the Study of the Liver in Vienna, Vertex Pharmaceuticals Incorporated today announced results from a Phase 1b clinical trial of the investigational oral hepatitis C virus polymerase inhibitor, VX-222. In the trial, treatment with VX-222 for three days was well-tolerated, with all adverse events being mild to moderate in severity.

16 Apr 2010

Advaxis initiates Phase 2 clinical trial of ADXS11-001 for treatment of CIN

Advaxis, Inc., the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company, initiated the Company's first clinical trial site in its randomized, single blind, placebo-controlled, Phase 2 clinical trial of ADXS11-001 for the treatment of cervical intraepithelial neoplasia.

16 Apr 2010

Æterna Zentaris Zentaris requests EMA Scientific Advice for Phase 3 program with perifosine

Æterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today announced that it has requested Scientific Advice from the European Medicines Agency (EMA) to assure the acceptability of the recently initiated Phase 3 programs for the development of its lead anticancer compound, perifosine, in its two lead indications, multiple myeloma and refractory advanced colorectal cancer.

15 Apr 2010

AVANIR Pharmaceuticals presents Phase III trial data of Zenvia for PBA at AAN Annual Meeting

AVANIR Pharmaceuticals, Inc. today announced the presentation of detailed data, including safety and tolerability data from the open-label extension as well as cardiac safety data from the double-blind phase of the Phase III confirmatory STAR trial evaluating the investigational drug Zenvia™ (dextromethorphan/quinidine) in the treatment of pseudobulbar affect (PBA). The data were presented in two posters at the American Academy of Neurology (AAN) Annual Meeting in Toronto, Canada.

15 Apr 2010

Study: Atorvastatin may slow down MS progression

A UCSF-led study examining the impact of statins on the progression of multiple sclerosis found a lower incidence of new brain lesions in patients taking the cholesterol-lowering drug in the early stages of the disease as compared to a placebo.

15 Apr 2010

New investigational treatment may help prevent involuntary outbursts in MS and ALS patients

Pseudobulbar affect (PBA) is a neurologic condition of involuntary, sudden and frequent episodes of laughing or crying and is quite common in patients with underlying neurologic diseases or injuries, especially those with multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS).

15 Apr 2010

New data from Pfizer Oncology's pipeline to be presented at AACR 2010

Pfizer Oncology announced today that it will present new data from the company's pipeline, including two novel, dual PI3K/mTOR inhibitors (PF-04691502 and PKI-587, also known as PF-05212384); crizotinib (PF-02341066), an ALK inhibitor that also inhibits c-MET; and PF-04605412, an anti-α5β1 inhibitor.

15 Apr 2010

Patients with RLS using rotigotine achieve sustained improvements

New data presented at the 62nd American Academy of Neurology annual meeting in Toronto, Canada, showed that patients with moderate to severe Restless Legs Syndrome using rotigotine achieved sustained improvements in symptoms over 5 years of treatment.

15 Apr 2010

Interim data from phase IIa clinical trial of IDX184 in HCV-infected patients

Idenix Pharmaceuticals, Inc., a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced interim data from a 14-day, phase IIa clinical trial evaluating IDX184, a novel liver-targeted nucleotide prodrug of 2'-methyl guanosine monophosphate, in HCV-infected patients.

15 Apr 2010

Rexahn Pharmaceuticals' Phase IIa clinical results of Serdaxin for MDD: Additional insights

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing potential best in class oncology and central nervous system (CNS) therapeutics, today offered additional commentary, clarifications and insights on yesterday's announcement of its Phase IIa clinical results of Serdaxin® in the treatment of major depressive disorder (MDD).

15 Apr 2010

Potential new drug for treatment of MS to be presented at AAN Annual Meeting

Researchers from Mount Sinai School of Medicine will present several studies at the American Academy of Neurology Annual Meeting, including a potential new drug for the treatment of multiple sclerosis and surprising trends showing a reduction in the disease's severity. The meeting will take place April 10-17 in Toronto.

15 Apr 2010

Investigational treatment with IGIV reduces brain atrophy in Alzheimer's patients

An investigational intervention using naturally ocurring antibodies in human blood has preserved the thinking abilities of a group of mild- to moderate-stage Alzheimer's patients over 18 months and significantly reduced the rate of atrophy (shrinkage) of their brains, according to a study performed at the NewYork-Presbyterian Hospital/Weill Cornell Medical Center.

15 Apr 2010

Efficacy data from Phase III STAR trial of Zenvia presented at AAN Annual Meeting

AVANIR Pharmaceuticals, Inc. today announced long-term efficacy data from the 12-week double-blind phase and the 12-week open-label extension phase of the confirmatory Phase III STAR trial evaluating Zenvia™ (dextromethorphan/quinidine) in the treatment of pseudobulbar affect in patients with underlying multiple sclerosis or amyotrophic lateral sclerosis.

15 Apr 2010

Targeted therapy MDV3100 is effective for patients with CRPC: Study

An experimental drug is showing promise for the treatment of men with an aggressive form of advanced prostate cancer. A new multicenter study has concluded that the targeted therapy MDV3100 is safe and effective for patients with castration-resistant prostate cancer, known for its poor prognosis and limited treatment options.

15 Apr 2010

Opexa Therapeutics presents key efficacy data on Tovaxin

Opexa Therapeutics, Inc., a company developing a novel T-cell therapy for multiple sclerosis, announced today that the Company presented key efficacy data at the American Academy of Neurology 62nd Annual Meeting held in Toronto, Canada.

15 Apr 2010

Synosia Therapeutics presents data from phase 2a clinical study of SYN-115 in PD

Synosia Therapeutics today announced the presentation of data from a phase 2a clinical study of the company's adenosine 2a receptor antagonist (SYN-115) in Parkinson's disease. The data demonstrate that SYN-115 significantly improves measures of motor and non-motor function in patients with Parkinson's disease either alone or in combination with levodopa.

15 Apr 2010

Catalyst Pharmaceutical Partners, NIDA to jointly conduct Phase II(b) trial of CPP-109 for cocaine addiction

Catalyst Pharmaceutical Partners, Inc. announced today that it has signed a definitive Clinical Trial Agreement (CTA) with the National Institute on Drug Abuse (NIDA) to jointly conduct a U.S. Phase II(b) clinical trial evaluating CPP-109, Catalyst's formulation of vigabatrin, for the treatment of cocaine addiction. As part of the CTA, NIDA, under their agreement with Veteran's Administration Cooperative Studies Program, will provide substantial resources for the estimated $10 million trial cost.

15 Apr 2010

Phase IIa clinical trial results of Serdaxin for treatment of MDD

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing potential best in class oncology and central nervous system therapeutics, today announced clinical results with its investigational new drug, Serdaxin®for the treatment of major depressive disorder.

15 Apr 2010

Phase II GAMMAGARD clinical study for Alzheimer's disease: 18-month results announced

Baxter International Inc. and New York-Presbyterian Hospital/Weill Cornell Medical Center today announced results of an 18-month Phase II clinical study of GAMMAGARD LIQUID and GAMMAGARD S/D [Immune Globulin Intravenous (Human)] (marketed as KIOVIG outside of the U.S.) for mild-to-moderate Alzheimer's disease. This marked the first announcement of clinical trial results measuring function and cognition in patients who received uninterrupted GAMMAGARD for a period of 18 months.

From Baxter International Inc. 15 Apr 2010

Placebo News and Research

Enrollment completed in Impax Pharmaceuticals' APEX-PD trial of IPX066

Vertex Pharmaceuticals announces results from Phase 1b clinical trial of VX-222

Advaxis initiates Phase 2 clinical trial of ADXS11-001 for treatment of CIN

Æterna Zentaris Zentaris requests EMA Scientific Advice for Phase 3 program with perifosine

AVANIR Pharmaceuticals presents Phase III trial data of Zenvia for PBA at AAN Annual Meeting

Study: Atorvastatin may slow down MS progression

New investigational treatment may help prevent involuntary outbursts in MS and ALS patients

New data from Pfizer Oncology's pipeline to be presented at AACR 2010

Patients with RLS using rotigotine achieve sustained improvements

Interim data from phase IIa clinical trial of IDX184 in HCV-infected patients

Rexahn Pharmaceuticals' Phase IIa clinical results of Serdaxin for MDD: Additional insights

Potential new drug for treatment of MS to be presented at AAN Annual Meeting

Investigational treatment with IGIV reduces brain atrophy in Alzheimer's patients

Efficacy data from Phase III STAR trial of Zenvia presented at AAN Annual Meeting

Targeted therapy MDV3100 is effective for patients with CRPC: Study

Opexa Therapeutics presents key efficacy data on Tovaxin

Synosia Therapeutics presents data from phase 2a clinical study of SYN-115 in PD

Catalyst Pharmaceutical Partners, NIDA to jointly conduct Phase II(b) trial of CPP-109 for cocaine addiction

Phase IIa clinical trial results of Serdaxin for treatment of MDD

Phase II GAMMAGARD clinical study for Alzheimer's disease: 18-month results announced

Industry Focus eBook - Analytical Chemistry (2nd Edition) eBook

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News